These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 31005623)

  • 21. Lung characteristics in elderly males and females patients with COPD: differences and optimal use of dry powder inhalers (DPIs).
    Terzano C; Oriolo F
    Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2708-2716. PubMed ID: 28678314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Aerodynamic characteristics of a dry powder inhaler at low inhalation flows using a mixing inlet with an Andersen Cascade Impactor.
    Nadarassan DK; Assi KH; Chrystyn H
    Eur J Pharm Sci; 2010 Mar; 39(5):348-54. PubMed ID: 20093182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of lung deflation with indacaterol plus glycopyrronium on ventricular filling in patients with hyperinflation and COPD (CLAIM): a double-blind, randomised, crossover, placebo-controlled, single-centre trial.
    Hohlfeld JM; Vogel-Claussen J; Biller H; Berliner D; Berschneider K; Tillmann HC; Hiltl S; Bauersachs J; Welte T
    Lancet Respir Med; 2018 May; 6(5):368-378. PubMed ID: 29477448
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A cross-sectional study to assess inhalation device handling and patient satisfaction in COPD.
    Miravitlles M; Montero-Caballero J; Richard F; Santos S; Garcia-Rivero JL; Ortega F; Ribera X
    Int J Chron Obstruct Pulmon Dis; 2016; 11():407-15. PubMed ID: 27013871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dose emission characteristics of placebo PulmoSphere® particles are unaffected by a subject's inhalation maneuver.
    Weers J; Ung K; Le J; Rao N; Ament B; Axford G; Maltz D; Chan L
    J Aerosol Med Pulm Drug Deliv; 2013 Feb; 26(1):56-68. PubMed ID: 22691109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of inhalation profile and throat geometry on predicted lung deposition of budesonide and formoterol (BF) in COPD: An in-vitro comparison of Spiromax with Turbuhaler.
    Chrystyn H; Safioti G; Keegstra JR; Gopalan G
    Int J Pharm; 2015 Aug; 491(1-2):268-76. PubMed ID: 26043823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Total emitted dose of salbutamol sulphate at different inhalation flows and inhalation volumes through different types of dry powder inhalers.
    Boshra MS; Almeldien AG; Salah Eldin R; Elberry AA; Abdelwahab NS; Nabil Salem M; Rabea H; Abdelrahim MEA
    Exp Lung Res; 2018; 44(4-5):211-216. PubMed ID: 30346848
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inspiratory flows through dry powder inhaler in chronic obstructive pulmonary disease: age and gender rather than severity matters.
    Malmberg LP; Rytilä P; Happonen P; Haahtela T
    Int J Chron Obstruct Pulmon Dis; 2010 Aug; 5():257-62. PubMed ID: 20714380
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multivariate Analysis of Effects of Asthmatic Patient Respiratory Profiles on the In Vitro Performance of a Reservoir Multidose and a Capsule-Based Dry Powder Inhaler.
    Buttini F; Pasquali I; Brambilla G; Copelli D; Alberi MD; Balducci AG; Bettini R; Sisti V
    Pharm Res; 2016 Mar; 33(3):701-15. PubMed ID: 26572643
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of an additional dose of indacaterol in COPD patients under regular treatment with indacaterol.
    Cazzola M; Segreti A; Stirpe E; Puxeddu E; Ora J; Rogliani P; Matera MG
    Respir Med; 2013 Jan; 107(1):107-11. PubMed ID: 23083839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence and predictors of suboptimal peak inspiratory flow rate in COPD patients.
    Harb HS; Laz NI; Rabea H; Abdelrahim MEA
    Eur J Pharm Sci; 2020 Apr; 147():105298. PubMed ID: 32151707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dose-ranging study of indacaterol in obstructive airways disease, with a tiotropium comparison.
    Rennard S; Bantje T; Centanni S; Chanez P; Chuchalin A; D'Urzo A; Kornmann O; Perry S; Jack D; Owen R; Higgins M
    Respir Med; 2008 Jul; 102(7):1033-44. PubMed ID: 18479895
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of Aerodynamic Particle Size Distribution Between a Next Generation Impactor and a Cascade Impactor at a Range of Flow Rates.
    Yoshida H; Kuwana A; Shibata H; Izutsu KI; Goda Y
    AAPS PharmSciTech; 2017 Apr; 18(3):646-653. PubMed ID: 27173989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inspiratory flow rates at different levels of resistance in elderly COPD patients.
    Janssens W; VandenBrande P; Hardeman E; De Langhe E; Philps T; Troosters T; Decramer M
    Eur Respir J; 2008 Jan; 31(1):78-83. PubMed ID: 17898020
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of combined indacaterol and glycopyrronium bromide (QVA149) for the treatment of COPD in Japan.
    Horita N; Kaneko T
    Int J Chron Obstruct Pulmon Dis; 2015; 10():813-22. PubMed ID: 25960646
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
    Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
    Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aerodynamic dose emission characteristics of dry powder inhalers using an Andersen Cascade Impactor with a mixing inlet: the influence of flow and volume.
    Yakubu SI; Assi KH; Chrystyn H
    Int J Pharm; 2013 Oct; 455(1-2):213-8. PubMed ID: 23892154
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhalation profiles in asthmatics and COPD patients: reproducibility and effect of instruction.
    Broeders ME; Molema J; Hop WC; Folgering HT
    J Aerosol Med; 2003; 16(2):131-41. PubMed ID: 12823907
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inspiratory Flow Parameters Through Dry Powder Inhalers in Healthy Volunteers and Patients with Chronic Obstructive Pulmonary Disease (COPD): Device Resistance Does Not Limit Use in COPD.
    Jõgi R; Mattila L; Vahteristo M; Takala A; Lähelmä S; Vartiainen VA; Lindqvist A
    Int J Chron Obstruct Pulmon Dis; 2021; 16():1193-1201. PubMed ID: 33958863
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biophysical model to predict lung delivery from a dual bronchodilator dry-powder inhaler.
    Dolovich MB; Kuttler A; Dimke TJ; Usmani OS
    Int J Pharm X; 2019 Dec; 1():100018. PubMed ID: 31517283
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.